Articles tagged with Prostate Cancer
University of York scientists identified how tiny regulatory molecules in cells make prostate cancers resistant to radiotherapy. By manipulating these critical micro-RNAs, it may be possible to kill more cancer stem cells and extend the lives of thousands of men.
Researchers found that men with low-risk prostate cancer are increasingly opting for active surveillance, while those with higher-risk tumors are receiving more aggressive treatments. This shift aims to reduce overtreatment and improve outcomes for patients.
Researchers identified a subset of genes known as biomarkers that define a genomic subtype of prostate cancer more common in African American men. This subtype signals a more aggressive disease and is defined by the absence or low levels of three genes: ERG, ETS, and SPINK1.
A new study found that increased radiation dose offers no survival benefit for patients with low-risk prostate cancer. In contrast, men with medium- and high-risk cancers saw improved survival rates with higher doses.
Researchers at Thomas Jefferson University discovered DNA-PKcs as a central regulator of metastatic processes in prostate cancer. The kinase modulates signaling networks that turn on metastatic processes, and its levels can predict poor outcomes in patients. A potential drug inhibitor, CC-115, is currently being tested in clinical trials.
Rates of active surveillance for low-risk prostate cancer increased sharply from 2010 to 2013, while high-risk disease was treated more appropriately with local treatments. Treatment patterns varied across individual practices, but suggest a genuine change in prostate cancer management in the US.
Researchers developed a smart sensor chip that can detect subtle differences in glycoprotein molecules, improving prostate cancer diagnosis accuracy and reducing false positives. The technology focuses on the carbohydrate part of the molecule, which is essential for detecting disease.
A UCLA review of common practices in prostate cancer has found that monitoring men with very low- and low-risk prostate cancers using watchful waiting or active surveillance is an effective approach for many patients. This approach could spare them the debilitating side effects of aggressive treatments, which are often used unnecessari...
RIT professor Hans Schmitthenner is designing molecular imaging compounds that selectively target prostate cancer cells, using contrast dyes for improved detection. The preclinical phase project aims to enhance image-directed biopsies, potentially reducing pain and side effects.
A small molecule agent PSMA-617 specifically attaches to prostate-specific membrane antigen on cancer cells, allowing for early detection of secondary tumors and monitoring response to therapy. This agent has shown promising results in PET scans and holds potential as a therapeutic option for hormone-resistant prostate carcinoma.
A new blood test has been developed to identify men with a genetically inherited risk of developing prostate cancer. The test analyzes DNA variants associated with increased risk and has shown promise in identifying high-risk individuals.
A Vanderbilt-led study found a 28% decline in new prostate cancer diagnoses in the U.S. following the USPSTF's recommendation to discontinue routine PSA screenings. This decrease was observed mainly among low-risk cancers and men over age 70.
A small clinical trial found that men with advanced prostate cancer and the AR-V7 gene variant respond to chemotherapy just as well as those without the variant. The study's findings may lead to improved treatment decision-making for patients with prostate cancer.
Researchers developed PSMA-617, a theranostic drug that detects prostate cancer and targets enzyme on cancer cells. The technology shows substantial reduction in radiotracer uptake and significant decrease in PSMA in blood after therapy, indicating positive response.
A novel radionuclide drug, PSMA-617, has been developed to target prostate-specific membrane antigen (PSMA) on prostate cancer cells, allowing for personalized diagnosis and therapy. The drug showed promising results in a human clinical trial, with effective imaging and therapeutic effects.
A new molecular imaging agent has been developed to detect prostate cancer that has spread to other tissues. The agent targets the PSMA enzyme, which is associated with prostate cancer, and has shown high accuracy in detecting disease sites, including those not identified by conventional methods.
A team of researchers at Cold Spring Harbor Laboratory has identified interleukin-6 as a key player in driving aggressive and hormone therapy-resistant prostate cancer. The discovery holds promise for developing targeted treatments and improving patient outcomes.
A study from Harvard T.H. Chan School of Public Health found that men with prostate cancer who followed a Western diet had a significantly higher risk of death, including prostate cancer-related mortality and overall mortality. In contrast, those on a 'prudent' diet had a lower risk of death from all causes.
Researchers at Cleveland Clinic have discovered a metabolite of the FDA-approved drug abiraterone that shows more anti-cancer properties than its precursor. The new compound, D4A, has been found to be more effective at killing aggressive prostate cancer cells, suggesting potential benefits for patients with metastatic prostate cancer.
A study has identified a possible new combination chemotherapy regimen for patients with advanced metastatic castrate-resistant prostate cancer. The treatment, combining cabazitaxel and carboplatin, significantly extended progression-free survival by 2.3 months compared to single-agent therapy.
Researchers found that Polyphenon E, a green tea extract, reduced combined rates of prostate cancer and atypical small acinar proliferation, as well as decreased levels of prostate-specific antigen in men with premalignant lesions. The study suggests that EGCG, the most abundant catechin in green tea, may play a role in these effects.
A new gene subgroup has been identified as a key driver of prostate cancer, allowing for the development of personalized treatment options. The study found that half of all prostate cancer patients have mutations in either C-MYC or L-MYC genes, which can influence disease aggression and treatment response.
A recent study has identified genetic abnormalities in prostate cancer that can be targeted with existing or potential drugs, providing a new approach to treatment. The research found that nearly all tumors had at least one genetic aberration, including mutations in the androgen receptor gene.
A comprehensive map of genetic mutations in advanced prostate cancers has been created, revealing that nearly 90% of patients have actionable mutations. This breakthrough could lead to targeted treatments and improve patient outcomes.
A large international study found that approximately 90% of cases with advanced prostate cancer harbor clinically actionable genetic anomalies. The researchers sequenced DNA and RNA from tumor biopsy samples to identify potential treatments, shedding light on this aggressive type of cancer.
Researchers have identified a molecule, PMEPA1, that promotes metastasis of advanced prostate cancer to the bone, which can lead to incurable conditions. The discovery may offer new targets for diagnosing and treating prostate cancer.
A national survey found that only one in ten Australians report being told about the risk of overdiagnosis by their doctors, while over 90% believe people should be informed. Overdiagnosis occurs when someone is diagnosed with a disease that will never cause harm due to unnecessary labelling and treatment.
Researchers at Johns Hopkins Medicine found that men with a history of asthma are 29% less likely to be diagnosed with lethal prostate cancer. Overall, asthmatic men were 36% less likely to die from the disease.
A new urine-based test, Mi-Prostate Score, has been shown to improve prostate cancer detection compared to traditional models based on PSA levels. The test combines PSA with two markers for prostate cancer, T2:ERG and PCA3, and can detect more aggressive forms of the disease.
The Prolaris test helps physicians determine the aggressiveness of prostate cancer, enabling personalized treatment plans. In a clinical validation study, the test showed that at the active surveillance threshold, predicted 10-year survival rates were 97% and risk of mortality was 3%.
Researchers have developed a new screening method for prostate cancer recurrence using spatial light interference microscopy. The study found that disorganized connective tissue surrounding the glands is a key indicator of higher risk for recurrence.
A new study led by Henry Ford Hospital researchers found that hospitals with low volumes of robot-assisted radical prostatectomies experienced a significantly higher complication rate compared to those with high volumes. The study suggests that current fee-for-service healthcare models may be to blame for this disparity.
A new study found that adding radiation therapy to treatments blocking testosterone's effects can control tumors and save lives for men with node-positive prostate cancer. This combination therapy reduced death rates by 50% compared to hormone therapy alone in patients with regional lymph nodes.
A new study by Moffitt researchers found that younger men and those with a lower body mass index are more prone to experiencing hot flashes during androgen deprivation therapy. The study analyzed patient characteristics and DNA to identify genetic factors associated with an increased number of hot flashes.
Myriad Genetics to present three studies supporting the use of Prolaris in predicting outcomes and personalizing treatment plans for men with localized prostate cancer. The tests demonstrate a new active surveillance threshold and validate an active surveillance threshold, showing potential for improved care.
Men who took statin drugs while receiving androgen deprivation therapy for prostate cancer had a longer disease control period compared to those who didn't take statins. The study found that statins could delay disease progression by reducing the tumor's available androgen pool.
Research suggests that statin use may delay resistance to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer. Statins block the uptake of dehydroepiandrosterone sulfate, a precursor of testosterone, thereby prolonging time to disease progression.
A recent study found that the Ga-68-PSMA-ligand PET/CT detected a large number of positive findings in patients with biochemical recurrence after radical prostatectomy, particularly at low PSA-values. The tracer's higher detection rates compared to other imaging methods suggest an early detection advantage for further clinical management.
Researchers found that blocking immune-suppressing cells allows chemotherapy to destroy prostate tumors in mouse models, achieving near complete remission. This novel combination therapy may have broader applications for other cancer types due to its effectiveness against metastatic and unresponsive cancers.
The ASCENDE-RT1 trial found that permanent radioactive implants (brachytherapy) reduced prostate cancer recurrence by 50% at five years compared to dose-escalated external beam radiotherapy. LDR-PB also showed an overall survival advantage, but with more urinary side effects.
Researchers found that MR tractography can accurately assess prostate cancer treatment response to androgen deprivation and radiation therapy. Higher tract densities indicate gland shrinkage and subsequent fibrosis after therapy.
A major trial has shown that olaparib can effectively treat advanced prostate cancer in men with defects in DNA repair genes. The results suggest that up to 30% of patients with terminal prostate cancer may benefit from the drug, which could become a treatment option if replication is confirmed in further trials.
Multiparametric MRI and ultrasound fusion enables targeted biopsies of high-suspicion foci with increased diagnostic accuracy for prostate cancer. For patients on active surveillance, this method better characterizes the prostate gland and detects higher-grade disease.
A research team led by Charles Sawyers and Howard Scher discovered novel antiandrogen enzalutamide, which extended survival among patients with metastatic castration-resistant prostate cancer. The AACR Team Science Award recognizes the team's innovative work in advancing cancer research.
Research found a significant association between obesity and increased prostate cancer risk in African American men, with the risk growing nearly four times as body-mass index (BMI) increased. Obesity was also linked to a higher risk of aggressive disease and prostate cancer death among this population.
A recent study found that obesity substantially increases prostate cancer risk in African-American men, while having a moderate effect on non-Hispanic white men. The research suggests that obesity may play an important role in the 'African-American race effect' on prostate cancer disparities.
A new Northwestern Medicine study found that walking at an easy pace for three hours a week improves prostate cancer survivors' fatigue, depression, and body weight issues. Non-vigorous walking also showed benefits in these areas, with brisk walking potentially leading to similar improvements.
Studies published in Journal of Cancer Survivorship found that walking three hours a week can improve hormone functioning and vitality in prostate cancer survivors. Regular physical activity also reduces symptoms of chemotherapy-induced peripheral neuropathy in colorectal cancer survivors, improving quality of life.
Researchers have discovered a protein biomarker that may indicate the presence of more aggressive prostate cancer. The biomarker, Runx2 phosphorylation, is closely associated with aggressive disease and has the potential to be a new drug target.
Researchers at the University of York have found a potential new treatment for organ-confined prostate cancer using low-temperature plasmas. The study, published in the British Journal of Cancer, suggests LTPs may be a viable alternative to current radiotherapy and photodynamic therapy treatments.
Researchers mapped genetic changes in tumor samples from 10 men with prostate cancer, revealing a common ancestral cell and shared gene faults. The study provides insight into how prostate cancer spreads and evolves, potentially leading to new treatment targets and personalized approaches.
A new study found that cells within metastases from prostate tumors can migrate to other body parts and form new sites of spread on their own. This challenges the long-held belief that cells with metastatic potential originate solely from the original tumor site.
A study published in JAMA Oncology found that high fitness levels in midlife were associated with a lower risk of lung and colorectal cancer. High fitness also reduced the risk of death from these cancers, as well as cardiovascular disease death among men diagnosed with cancer.
Implementing video-based decision aids in urology led to fewer elective surgeries for benign prostatic hyperplasia and localized prostate cancer. Rates of surgical intervention declined by 32% for treated BPH patients and 27% for localized prostate cancer patients.
Researchers found delayed radiation therapy offers no protective benefit and may increase risk of complications, contradicting the long-held view. Adjuvant therapy soon after prostate removal is effective in curing patients with low-grade disease.
Researchers found that vitamin D supplements slowed tumor growth and reduced inflammation in men with low-grade prostate cancer. The study suggests that vitamin D may improve treatment outcomes for these patients by reducing the need for aggressive treatments.
Washington State University researchers have discovered a mechanism by which omega-3 fatty acids inhibit the growth and spread of prostate cancer cells. The findings suggest that a potential new anti-cancer drug could be developed to target this process.
A recent study defines a distinct subtype of aggressive prostate cancer marked by MAP3K7 and CHD1 gene loss, accounting for 10% of all cases and 25% of fatal outcomes. Researchers used stem-cell models to show that these genetic changes disrupt healthy tissue formation, leading to hybrid cells with aggressive characteristics.
Researchers developed a nanotechnology-based method to assess prostate cancer risk, enabling doctors to identify aggressive forms of the disease and tailor treatment recommendations. The study's findings suggest that this approach may improve patient outcomes by minimizing side effects.
A study published in JAMA Oncology found high rates of inappropriate imaging for both prostate cancer and breast cancer, suggesting that regional culture and infrastructure play a role in health care utilization patterns. The researchers estimated that 30% of healthcare resources in the US do not improve patient health.